Schwarz Builds its Business in the Public Eye
Schwarz Pharma is a publicly-held mid-sized pharmaceutical company in Germany with a business model that emphasizes its marketing and sales strengths in Germany. It does little R&D of its own, preferring to license in products from outside. To compete against others seeking to license in products, it offers its strengths in the German market. Its recent deal with Novartis AG to co-market the hypertension drug valsartan is an example of this strategy.
You may also be interested in...
Gene therapy remains attractive when data show new technologies can advance the field, but gene regulation, editing and RNA therapies are grabbing investors’ attention, panelists said at ARM’s Cell and Gene Meeting on the Mesa.
Gilead looks set to expand its lead position in the triple-negative breast cancer (TNBC) market in Europe with a positive opinion for Trodelvy from the CHMP.
Company seeks to avoid Medicaid “best price” implications by administering the program through an insurance policy with AIG, which is handling claims for refunds and processing payments.